Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naive Japanese patients with type 2 diabetes

被引:6
|
作者
Ohta, Akio [1 ]
Ohshige, Toshihiko [1 ]
Sakai, Kensuke [1 ]
Nakamura, Yuta [1 ]
Tenjin, Ayumi [1 ]
Tsukiyama, Shuichi [1 ]
Terashima, Yuko [1 ]
Matsubara, Fumiaki [1 ]
Kawata, Takehiro [1 ]
Nagai, Yoshio [1 ]
Tanaka, Yasushi [1 ]
机构
[1] St Marianna Univ, Sch Med, Div Endocrinol & Metab, Dept Internal Med,Miyamae Ku, Kawasaki, Kanagawa 2168511, Japan
关键词
1,5-anhydroglucitol; glycoalbumin; mitiglinide; sitagliptin; voglibose; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; ALPHA-GLUCOSIDASE INHIBITORS; FASTING PLASMA-GLUCOSE; FIXED-DOSE COMBINATION; INSULIN-SECRETION; POSTPRANDIAL HYPERGLYCEMIA; NATEGLINIDE; SULFONYLUREAS; RESISTANCE; RISK;
D O I
10.1517/14656566.2013.842554
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The postprandial glucose (PPG) level is reduced by alpha-GIs, glinides and DPP4Is through different pharmacological actions. The aim of this study was to compare the effect of sitagliptin (S) versus that of the combination of mitiglinide and voglibose (M+V) on markers of glycemic control. Research design and methods: A randomized cross-over trial was performed in 20 patients with drug-naive type 2 diabetes. The patients were randomized to receive S (50 mg/day) or M+V (1 tablet 3 times daily). Treatment was continued for 8 weeks, after which they were switched to the other regimen and treated for another 8 weeks. At baseline, after the first regimen, and after the second regimen, a meal test was performed. Main outcome measures: The markers of glycemic control were examined. Results: Reduction of glucose excursion was significantly greater with M+V than with S. HbA(1c) did not change with either regimen. However, 1,5-anhydroglucitol showed a significant increase from baseline with both regimens (7.9 +/- 4.3 mu g/ml at baseline vs. 10.6 +/- 5.5 with S, p < 0.05 and 15.1 +/- 6.2 with M+V, p < 0.01). Compared with baseline, glycoalbumin was significantly reduced by M+V, but not S (19.6 +/- 2.9% at baseline vs. 17.3 +/- 3.8% with M+V, p < 0.05). Conclusion: M+V achieved better control of PPG excursion than S.
引用
收藏
页码:2315 / 2322
页数:8
相关论文
共 50 条
  • [31] Efficacy and safety of saxagliptin in drug-naive Asian patients with type 2 diabetes mellitus: a randomized controlled trial
    Pan, Chang Yu
    Yang, Wenying
    Tou, Conrad
    Gause-Nilsson, Ingrid
    Zhao, June
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2012, 28 (03) : 268 - 275
  • [32] Add-on Treatment with Mitiglinide Improves Residual Postprandial Hyperglycemia in Type 2 Diabetic Patients Receiving the Combination Therapy with Insulin Glargine and Sitagliptin
    Murakami, Takaaki
    Nambu, Takuo
    Kato, Tomoko
    Matsuda, Yuki
    Yonemitsu, Shin
    Muro, Seiji
    Oki, Shogo
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2015, 235 (04) : 255 - 260
  • [33] Levels of metabolic markers in drug-naive prediabetic and type 2 diabetic patients
    Akour, Amal
    Kasabri, Violet
    Boulatova, Nailya
    Bustanji, Yasser
    Naffa, Randa
    Hyasat, Dana
    Khawaja, Nahla
    Bustanji, Haidar
    Zayed, Ayman
    Momani, Munther
    ACTA DIABETOLOGICA, 2017, 54 (02) : 163 - 170
  • [34] A High Level of Circulating Valine Is a Biomarker for Type 2 Diabetes and Associated with the Hypoglycemic Effect of Sitagliptin
    Liao, Xiaoyu
    Liu, Bingyao
    Qu, Hua
    Zhang, LinLin
    Lu, Yongling
    Xu, Yong
    Lyu, Zhaohui
    Zheng, Hongting
    MEDIATORS OF INFLAMMATION, 2019, 2019
  • [35] Sitagliptin versus saxagliptin in decompensated type 2 diabetes mellitus patients
    Asti, Antonio
    D'Alessandro, Alessandra
    Zito, Francesco Paolo
    Nardi, Salvatore
    Sarnelli, Giovanni
    Maresca, Giorgio
    D'Alessandro, Giuseppe
    ITALIAN JOURNAL OF MEDICINE, 2016, 10 (01) : 36 - 41
  • [36] Cost-effectiveness of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients With Type 2 Diabetes Mellitus
    Brown, Stephen T.
    Grima, Daniel Grima
    Sauriol, Luc
    CLINICAL THERAPEUTICS, 2014, 36 (11) : 1576 - 1587
  • [37] Effect of sitagliptin on glycemic control in patients with type 2 diabetes
    Rahmah, Abbas Mahdi
    WORLD FAMILY MEDICINE, 2015, 13 (06): : 20 - 25
  • [38] Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination
    Ono, Yuri
    Kamoshima, Hikaru
    Nakamura, Akinobu
    Nomoto, Hiroshi
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (13) : 1785 - 1795
  • [39] Effect of Mitiglinide on Glycemic Control over 52 Weeks in Japanese Type 2 Diabetic Patients Insufficiently Controlled with Pioglitazone Monotherapy
    Kaku, Kohei
    Tanaka, Shun-ichi
    Origasa, Hideki
    Kikuchi, Masatoshi
    Akanuma, Yasuo
    ENDOCRINE JOURNAL, 2009, 56 (06) : 739 - 746
  • [40] Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy
    Lage, Maureen J.
    Fabunmi, Rosalind
    Boye, Kristina S.
    Misurski, Derek A.
    ADVANCES IN THERAPY, 2009, 26 (02) : 217 - 229